The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats

Cell Biochemistry and Function

Volumn 26, Issue 4, 2008, Pages 478-485

  Kavak, Servet ^a   Ayaz, Lokman ^b   Emre, Mustafa ^a   Inal, Tamer ^a   Tamer, Lülüfer ^b   Günay, Ismail ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

3 nitrotyrosine; Diabetes mellitus; Malondialdehyde; Oxidative stress; Rosiglitazone

Indexed keywords

3 NITROTYROSINE; GLUCOSE; HEMOGLOBIN A1C; LIPID; MALONALDEHYDE; ROSIGLITAZONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; HEART VENTRICLES; HEMOGLOBIN A, GLYCOSYLATED; LIPID METABOLISM; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN; THIAZOLIDINEDIONES; TYROSINE;

RATTUS;

EID: 46749101381     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1469     Document Type: Article

References (46)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to year 2010. Diabetic Med 1997; 14: 1-85.
2. Defronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1998; 37: 667-873.
3. Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.
4. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286: 1597-1602.
5. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000; 23: 1278-1283.
6. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
7. Zinman B, Harris SB, Gerstein HC, et al. Preventing type 2 diabetes using combination therapy: design and methods of the Canadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes Obes Metab 2006; 8: 531-537.
8. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-1837.
9. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPAR gamma associated with severe insulin resistance diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
10. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombi-n-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
11. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
12. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T. B-cell mass dynamics in zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
13. Barnett AH, Grant PJ, Hitman GA, et al. Indo-Asian trial investigators rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet Med 2003; 20: 387-393.
14. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25: 1810-1816.
15. Bonnevie-Nielsen MW, Lernmark A. A major loss in islet mass and B-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. Diabetes 1981; 30: 424-429.
16. Ramesh B, Pugalendi KV. Influence of umbelliferone on membrane-bound ATPases in streptozotocin-induced diabetic rats. Pharmacol Rep 2007; 59: 339-348.
17. Sawant SP, Dnyanmote AV, Shankar K, Limaye PB, Latendresse JR, Mehendale HM. Potentiation of carbon tetrachloride hepatotoxicity and lethality in Type 2 diabetic rats. J Pharmacol Exp Ther 2004; 308: 694-704.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Yagi K. Lipid peroxides and related radicals in clinical medicine. In Free radicals in diagnostic medicine, Armstrong D (ed.). Plenum: New York, 1994; 1-15.
20. Ünlü A, Türkozkan N, Çimen B, Karabiçak U, Yaman H. The effects of Escherichia coli-derived lipopolysaccharides on plasma levels of malondialdehyde and 3-nitrotyrosine. Clin Chem Lab Med 2001; 39: 491-493.
21. Young PW, Buckle DR, Cantello BC. Identification of high affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-759.
22. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
23. Lehmann JM, Moore LB, Smith-Oliver TA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome prolifemtor-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
24. SaItieI AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
25. American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998; 21: 310-314.
26. Calkin AC, Forbes JM, Smith CM, et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol. 2005; 25: 1903-1909.
27. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type-2 diabetes mellitus. Drugs 2002; 62: 1805-1837.
28. Izzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin mediated hepatic glucose uptake and their relation to visceral fat in type-2 diabetes. Diabetes Care 2003; 26: 2069-2074.
29. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 2: 1151-1168.
30. Chaudhry J, Ghosh NN, Roy K, Chandra R. Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life Sci 2007; 80: 1135-1142.
31. Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995; 6: 153-160.
32. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993; 92; 141-146.
33. Staels B, Auwerx J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr Pharm Des 1997; 3: 1-14.
34. Wang S, Jiang JL, Hu CP, Zhang XJ, Yang DL, Li YJ. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells. Diabetes Metab Res Rev 2007; 23: 157-164.
35. Van Wijk JP, Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-1749.
36. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000; 23: 557.
37. Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Prac 2006; 71: 52-58.
38. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type-2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 1358-1360.
39. Myerson AB, Hundal RS, Dufour S, Lebon V, Befory D, Cline GW. The effects of rosiglitazone on insulin sensitivity lipolysis and hepatic and skeletal muscle triglyceride content in patients with type-2 diabetes. Diabetes 2002; 51: 797-802.
40. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2004; 286: 742-748.
41. Radi R, Denicola A, Alvarez B, Ferrer-Sueta G, Rubbo H. The biological chemistry of peroxynitrite. In Introduction and Overview, Ignarro JL (ed.). Academic Press: San Diego, California, USA, 2000; 57-82.
42. Filippo CD, Cuzzocrea S, Rossi F, Marfella R, D'Amico M. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev 2006; 24: 77-87.
43. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
44. Shiojiri T, Wada K, Nakajima A, et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 2002; 448: 231-238.
45. Tao L, Liu HR, Gao E, et al. Antioxidative antinitrative and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108: 2805-2811.
46. Mahboob M, Rahman MF, Grover P. Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic patients. Singapore Med J 2005; 46: 322-324.